AI Article Synopsis
- Omalizumab is a monoclonal antibody that lowers IgE levels and affects immune cell receptors, used primarily for allergic asthma and urticaria.
- According to GINA guidelines, it's recommended as an alternative to systemic corticosteroids for uncontrolled asthma.
- Ongoing trials are exploring its effectiveness for other allergic conditions, and more research is needed to determine the best treatment duration and identify patients who will benefit most.
Article Abstract
Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating IgE and expression of IgE high affinity receptor (FCɛRI) on mast cells and basophils. Its role in the therapy of allergic asthma and urticaria is well established. According to GINA guidelines, omalizumab should be considered as an important alternative to systemic corticosteroids in uncontrolled asthma. Several ongoing trials will evaluate omalizumab efficacy in the treatment of other allergic diseases and conditions. Further studies are needed to answer several practical questions on the optimal duration of treatment and possible biomarkers to predefine a cohort of responders to this therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952053 | PMC |
| http://dx.doi.org/10.5114/pdia.2014.40657 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!